-
Feb 19, 2025 | 
nature.com | Sobha Sivaprasad
We are grateful to Chen et al. for their commendations and suggestions for progressing this field. Competing risks (events that preclude primary event occurrence) feature in almost all Kaplan–Meier analyses and hazard estimates can be susceptible to competing risk bias; but only if featured frequently and treated as censored events [1]. We can fortunately offer reassurance that the risks nominated by Chen et al. have minimal if any, impact on our results presented.
-
Jan 31, 2025 | 
nature.com | Sobha Sivaprasad
In the phase 2/3 PHOTON trial, patients with diabetic macular oedema who received aflibercept 8 mg every 12 or 16 weeks achieved similar visual and anatomic improvements to those treated with aflibercept 2 mg every 8 weeks at Week 48. AcknowledgementsThe authors thank Yazmin Madrigal for visual graphics and layout support. The authors also acknowledge Disha Patel, PhD, for medical writing assistance. FundingThe PHOTON trial (NCT04429503) was co-funded by Regeneron Pharmaceuticals, Inc.
-
Jan 13, 2025 | 00397-8/abstract?rss=yes&sz=64)
thelancet.com | Sobha Sivaprasad
References1. Scanlon, PHThe English national screening programme for sight-threatening diabetic retinopathyJ Med Screen. 2008; 15:1-42. Liew, G ∙ Michaelides, M ∙ Bunce, CA comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010BMJ Open. 2014; 4, e0040153. Leal, J ∙ Luengo-Fernandez, R ∙ Stratton, IM ∙ et al.
-
Aug 30, 2024 | 
nature.com | Sobha Sivaprasad |Clare Bailey |Giuliana Silvestri
AbstractSome eyes with neovascular age-related macular degeneration (nAMD) and centre-involving diabetic macular oedema (DMO) fail to respond sufficiently or lose response over time to standard of care intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. This paper explores clinical scenarios for switching to dual action angiopoietin-2 (Ang-2)/VEGF-A inhibitor faricimab (Vabysmo, Roche Products Limited) in previously anti-VEGF-treated patients.
-
Aug 26, 2024 | 
nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more
The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).
-
Jul 20, 2024 | 
nature.com | Keean Nanji |Amin Hatamnejad |Mark Phillips |Dena Zeraatkar |Tien Yin Wong |Robyn Guymer | +8 more
The fragility index (FI) of a meta-analysis evaluates the extent that the statistical significance can be changed by modifying the event status of individuals from included trials. Understanding the FI improves the interpretation of the results of meta-analyses and can help to inform changes to clinical practice. This review determined the fragility of ophthalmology-related meta-analyses. Meta-analyses of randomized controlled trials with binary outcomes published in a journal classified as ‘Ophthalmology’ according to the Journal Citation Report or an Ophthalmology-related Cochrane Review were included. An iterative process determined the FI of each meta-analysis. Multivariable linear regression modeling evaluated the relationship between the FI and potential predictive factors in statistically significant and non-significant meta-analyses. 175 meta-analyses were included. The median FI was 6 (Q1–Q3: 3–12). This meant that moving 6 outcomes from one group to another would reverse the study’s findings. The FI was 1 for 18 (10.2%) of the included meta-analyses and was ≤5 for 75 (42.4%) of the included meta-analyses. The number of events (p < 0.001) and the p-value (p < 0.001) were the best predictors of the FI in both significant and non-significant meta-analyses. The statistical significance of meta-analyses in ophthalmology often hinges on the outcome of a few patients. The number of events and the p-value are the most important factors in determining the fragility of the evidence. The FI is an easily interpretable measure that can supplement the reader’s understanding of the strength of the evidence being presented. CRD42022377589
-
May 31, 2024 | 
bmjopen.bmj.com | Magdalena Niestrata |Jonathan J Deeks |Yemisi Takwoingi |Sobha Sivaprasad
AbstractIntroduction The diagnosis of neovascular age-related macular degeneration (nAMD), the leading cause of visual impairment in the developed world, relies on the interpretation of various imaging tests of the retina. These include invasive angiographic methods, such as Fundus Fluorescein Angiography (FFA) and, on occasion, Indocyanine-Green Angiography (ICGA).
-
Apr 25, 2024 | 
jamanetwork.com | Ruth Hogg |Sobha Sivaprasad |Robin A Wickens |Sean O’Connor
Key PointsQuestion Can any of the following visual function tests detect reactivation of neovascular age-related macular degeneration sufficiently well to enable monitoring at home to be implemented, including the KeepSight Journal (International Macular and Retinal Foundation), the MyVisionTrack (Genentech) vision-monitoring mobile app, and the MultiBit app (Visumetrics).
-
Apr 25, 2024 | 
jamanetwork.com | Kevin J. Blinder |Ruth Hogg |Sobha Sivaprasad |Robin A Wickens
Home-Monitoring Vision Tests to Detect Active Neovascular AMD Ruth E. Hogg, PhD; Sobha Sivaprasad, DM; Robin Wickens, PhD; Sean O’Connor, PhD; Eleanor Gidman, PhD; Elizabeth Ward, PhD; Charlene Treanor, PhD; Tunde Peto, PhD; Ben J. L. Burton, MD; Paul Knox, PhD; Andrew J. Lotery, MD; Michael Donnelly, PhD; Chris A. Rogers, PhD; Barnaby C.
-
Jun 23, 2023 | 
bmjopen.bmj.com | Sobha Sivaprasad
